List of Striverdi Respimat drug patents

Striverdi Respimat is owned by Boehringer Ingelheim.

Striverdi Respimat contains Olodaterol Hydrochloride.

Striverdi Respimat has a total of 13 drug patents out of which 0 drug patents have expired.

Striverdi Respimat was authorised for market use on 31 July, 2014.

Striverdi Respimat is available in spray, metered;inhalation dosage forms.

Striverdi Respimat can be used as treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema.

The generics of Striverdi Respimat are possible to be released after 16 October, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(8 months from now)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(9 months from now)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(2 years from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(8 months from now)

US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(8 months from now)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 6 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(2 years from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2014

Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STRIVERDI RESPIMAT family patents

20

United States

17

European Union

12

Germany

10

China

8

Japan

7

Spain

7

Canada

6

Australia

6

Denmark

5

Austria

5

Korea, Republic of

5

Brazil

5

Poland

5

Cyprus

5

Mexico

5

Slovenia

5

South Africa

5

Portugal

4

Argentina

4

Colombia

4

Norway

4

New Zealand

3

Ukraine

3

Israel

3

Peru

3

EA

3

Croatia

3

Taiwan, Province of China

3

Ecuador

2

Hong Kong

2

Malaysia

2

Yugoslavia

2

Uruguay

2

Russia

2

ME

1

RS

1

Lithuania

1

Luxembourg

1

Netherlands

1

Hungary

1

Egypt

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in